The company expects 2008 world-wide sales to be driven by its Singulair respiratory products, Cozaar/Hyzaar hypertension products, and vaccines. ...
The company estimates fiscal 2007 sales of $4.1 - $4.3 billion from Respiratory drug SINGULAIR, $3.2 - $3.4 billion from Hypertension medicine COZAAR/HYZAAR ...
all 2 news articles
... cyclical pressure in US construction, and a projected EPS hit of 41 cents a share in 2010 following pharma patent expirations for Cozaar/Hyzaar. ...
The drug, losartan (brand name Cozaar), lowers the activity of the protein transforming growth factor beta (TGFß), which researchers have found to be the ...
Sales in the quarter were led by Singulair, at $1 billion; the blood pressure medicines Cozaar and Hyzaar, at $814 million; Fosamax, with $725 million in ...
... to lose licensing revenue from hyper-tension drugs Cozaar and Hyzaar from 2010, when the patent protection for the drugs expires in the United States. ...
all 7 news articles
... in the next three years, including the osteoporosis drug Fosamax and blood pressure drug Cozaar, which generated a combined $6.3 billion last year. ...
The drug turned on the same blood pressure pathway pills like Cozaar and Diovan aim to block, turning up the production of a chemical called aldosterone ...